Table 1.
Antibiotic resistance profile of the 18 C. sakazakii study isolates.
| Isolates | Antibiotics | MIC * (µg) | Antibiotic Resistance Profile |
|---|---|---|---|
| CFS1154 | FAZ ** | 8 | R *** |
| MIN | 4 | R | |
| CFS1155 | MIN | 4 | R |
| CFS1156 | FAZ | 8 | R |
| MIN | 2 | R | |
| CFS1157 | FAZ | 8 | R |
| MIN | 4 | R | |
| CFS1158 | FAZ | 16 | R |
| MIN | 4 | R | |
| CFS1159 | FAZ | 8 | R |
| MIN | 2 | R | |
| CFS1160 | FAZ | 8 | R |
| MIN | 2 | R | |
| CFS1161 | FAZ | 8 | R |
| MIN | 2 | R | |
| CFS1169 | FAZ | 8 | R |
| MIN | 2 | R | |
| CFS1176 | FAZ | 16 | R |
| MIN | 2 | R | |
| A/S 2 | 8/4 | R | |
| CFS1297 | FAZ | 4 | R |
| MIN | 4 | R | |
| CFS1304 | FAZ | 16 | R |
| MIN | 4 | R | |
| CIP | 2 | R | |
| CFS1322 | FAZ | 8 | R |
| MIN | 4 | R | |
| TAZ | 2 | I | |
| AXO | 1 | S | |
| CFS1362 | FAZ | 8 | R |
| MIN | 4 | R | |
| CFS1328 | FAZ | 8 | R |
| MIN | 4 | R | |
| CFS1370 | FAZ | 8 | R |
| MIN | 4 | R | |
| CFS1377 | FAZ | 8 | R |
| MIN | 2 | R | |
| CFS2786 | AMP | 16 | R |
| FAZ | 16 | R | |
| C/T | 4 | R | |
| CIP | 2 | R | |
| MIN | 4 | R | |
| CZA | 16/4 | R | |
| NIT | 64 | R | |
| A/S 2 | 16/8 | R | |
| CFS2788 | FAZ | 8 | R |
| MIN | 4 | R | |
| CIP | 2 | R |
* MIC (Minimum inhibitory concentration)—the lowest concentration of the antibiotics that can effectively inhibit growth of the tested microorganism. ** FAZ: Cefazolin, MIN: Minocycline, TGC: Tigecycline, TAZ: Ceftazidime, CIP: Ciprofloxacin, AXO: Ceftriaxone, C/T: Ceftaozolone/Tazobactam 4, NIT: Nitrofurantoin, CZA: Ceftazidime/Avibactam, A/S 2: Ampicillin/Sulbactam 2:1 ratio, AMP: Ampicillin. *** R: resistant; S: susceptible; I: intermediate resistance.